Back to Studies

IMPAACT 2041

Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy

Study Status

In Development

IND Number

TBD

Clinical Trials Link

TBD

Primary Protocol Team Members

Ahizechukwu Eke Study Chair
Nathan Furukawa Study Vice-Chair
Renee Browning DAIDS Medical Officer
Christine Chiou DAIDS Medical Officer
Franklin Yates NICHD Medical Officer
Sonia Lee NICHD Medical Officer

Summary

IMPAACT 2041 is a Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in People with Hepatitis C During Pregnancy. The study is designed to evaluate the pharmacokinetics and safety of GLE/PIB during pregnancy and postpartum, and will follow pregnant people and their infants through three months postpartum. 

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...